SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+6.36%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$312M
AUM Growth
+$312M
(+7.3%)
Cap. Flow
+$7.81M
Cap. Flow
% of AUM
2.5%
Top 10 Holdings %
Top 10 Hldgs %
56.55%
Holding
35
New
5
Increased
15
Reduced
12
Closed
2
Top Buys
| 1 |
Elevance Health
ELV
|
$5M |
| 2 |
Bristol-Myers Squibb
BMY
|
$4.2M |
| 3 |
Amgen
AMGN
|
$4.05M |
| 4 |
Tandem Diabetes Care
TNDM
|
$3.46M |
| 5 |
Johnson & Johnson
JNJ
|
$3.32M |
Top Sells
| 1 |
Medtronic
MDT
|
$10.3M |
| 2 |
Gilead Sciences
GILD
|
$6.44M |
| 3 |
Pfizer
PFE
|
$5.83M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$5.66M |
| 5 |
Zimmer Biomet
ZBH
|
$2.73M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $26.5M | 8.5% | 435,000 +68,834 | +19% | +$4.2M |
|
|
2
Pfizer
PFE
$141B
| $23.4M | 7.51% | 925,000 -230,000 | -20% | -$5.83M |
|
3
Becton Dickinson
BDX
$55.3B
| $18.8M | 6.02% | 82,000 +6,000 | +8% | +$1.37M |
|
|
4
Medtronic
MDT
$119B
| $18.4M | 5.9% | 205,000 -115,000 | -36% | -$10.3M |
|
|
5
Amgen
AMGN
$155B
| $18.4M | 5.89% | 59,000 +13,000 | +28% | +$4.05M |
|
|
6
Johnson & Johnson
JNJ
$427B
| $16.3M | 5.21% | 98,000 +20,000 | +26% | +$3.32M |
|
|
7
Gilead Sciences
GILD
$140B
| $15.7M | 5.02% | 140,000 -57,500 | -29% | -$6.44M |
|
8
CVS Health
CVS
$92.8B
| $13.7M | 4.38% | 202,000 -15,000 | -7% | -$1.02M |
|
|
9
Zimmer Biomet
ZBH
$21B
| $12.9M | 4.12% | 113,631 -24,083 | -17% | -$2.73M |
|
|
10
Elevance Health
ELV
$71.8B
| $12.5M | 4.01% | 28,779 +11,500 | +67% | +$5M |
|
11
Cardinal Health
CAH
$35.5B
| $12.1M | 3.88% | 88,000 | – | – |
|
12
Centene
CNC
$14.3B
| $10.7M | 3.44% | 177,000 +7,000 | +4% | +$425K |
|
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.71M | 3.11% | 137,348 -80,000 | -37% | -$5.66M |
|
14
Incyte
INCY
$16.5B
| $9.63M | 3.08% | 159,000 -38,400 | -19% | -$2.33M |
|
15
Edwards Lifesciences
EW
$47.8B
| $8.92M | 2.86% | 123,000 +24,000 | +24% | +$1.74M |
|
16
Bruker
BRKR
$5.16B
| $8.85M | 2.83% | 211,970 +53,000 | +33% | +$2.21M |
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $8.62M | 2.76% | 285,842 +50,000 | +21% | +$1.51M |
|
18
Baxter International
BAX
$12.7B
| $8.48M | 2.72% | 247,650 +89,000 | +56% | +$3.05M |
|
19
Qiagen
QGEN
$10.1B
| $7.51M | 2.4% | 187,000 -16,993 | -8% | -$682K |
|
20
Humana
HUM
$36.5B
| $6.62M | 2.12% | 25,000 +11,000 | +79% | +$2.91M |
|
21
Tenet Healthcare
THC
$16.3B
| $5.78M | 1.85% | 43,000 +21,000 | +95% | +$2.82M |
|
22
Elanco Animal Health
ELAN
$9.12B
| $5.01M | 1.6% | 477,073 +200,166 | +72% | +$2.1M |
|
23
GE HealthCare
GEHC
$33.7B
| $5M | 1.6% | 62,000 +12,000 | +24% | +$969K |
|
24
PTC Therapeutics
PTCT
$3.92B
| $4.7M | 1.51% | 92,250 +27,000 | +41% | +$1.38M |
|
|
25
Tandem Diabetes Care
TNDM
$845M
| $3.46M | 1.11% | +180,523 | New | +$3.46M |
|